Intellia Therapeutics Inc sell The Goldman Sachs Group, Inc.
Start price
28.02.25
/
50%
€9.21
Target price
28.02.26
€8.65
Performance (%)
19.35%
End price
01.03.26
€10.99
Summary
This prediction ended on 01.03.26 with a price of €10.99. The SELL prediction by The_Goldman_Sachs_Gr finished with a performance of 19.35%. The_Goldman_Sachs_Gr has a follow-up prediction for Intellia Therapeutics Inc where he still thinks Intellia Therapeutics Inc is a Sell. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -4.970% | -4.970% | -15.436% |
| iShares Core DAX® | 1,72 % | 3,37 % | 5,89 % |
| iShares Nasdaq 100 | -4,56 % | -4,24 % | 21,39 % |
| iShares Nikkei 225® | -7,12 % | -11,87 % | 42,36 % |
| iShares S&P 500 | -0,89 % | 1,69 % | 19,49 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "sell" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $9.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.14
28.04.26
28.04.26
-
28.04.27
28.04.27
-14.18%
28.07.26
28.07.26
